RecruitingNCT05965115

The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study

The China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) --A Multicenter Observational Study

Sponsor

Shanghai Zhongshan Hospital

Enrollment

10,000 participants

Start Date

Jul 1, 2023

Study Type

OBSERVATIONAL

Conditions

Multiple Myeloma Monoclonal Gammopathy of Undetermined Significance

Summary

The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for monoclonal gammopathy (M-protein) in first-degree relatives of patients with multiple myeloma in China population, and establish a prospective cohort of individuals with monoclonal gammopathy of undetermined significance (MGUS), a precursor conditions to multiple myeloma. We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (the CHAPERONE study) is screening close family members (parents, children, biological siblings) of people diagnosed with multiple myeloma — a blood cancer — to check for early warning signs called M-proteins in the blood. Finding these proteins early may allow doctors to monitor and potentially intervene before myeloma develops. **You may be eligible if...** - You are 18 or older - You have a first-degree relative (parent, child, or biological sibling) who has been diagnosed with multiple myeloma - You are willing to undergo screening blood tests and follow-up **You may NOT be eligible if...** - You have already been diagnosed with multiple myeloma or a related blood condition - You are unwilling or unable to follow the study's procedures and follow-up schedule - You do not have a qualifying first-degree relative with myeloma Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTSample of Blood

All participants will receive M-protein screening by serum electrophoresis. Individuals with detected M-protein will undergo further diagnostic tests to determine their accurate diagnosis. Patients with monoclonal gammopathy of undetermined significance (MGUS) would be carefully assessed and followed up.